Van Andel Research Institute   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Grand Rapids MI United States (1996)

Organization Overview

First Clinical Trial
2002
NCT00202800
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Van Andel Institute Stand Up to Cancer Team | Van Andel Research Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ductal (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Cholangiocarcinoma (Phase 1)

Gallbladder Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lung Neoplasms (Phase 1)

Medulloblastoma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neuroblastoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 13